Schizandrin의 신혈관형성억제에 의한 항암효과 (Antitumor Effect of Schizandrin by Inhibiting Angiogenesis)

서지정보

· 발행기관 : 한의병리학회
· 수록지 정보 : 동의생리병리학회지 / 26권 / 5호 / 687 ~ 692페이지
· 저자명 : 윤미소, 김도윤, 유호진, 박주훈, 장상희, 원경종, 김보경, 이환명

초록

Schizandra chinensis extract has been known to possess a variety of efficacy including antitumor. However, it remains unclear how schizandrin, which is a major biological active ingredient of Schizandra chinensis, exerts antitumor effect. This study was designed to investigate the mechanism by which schizandrin inhibits tumor growth and metastasis. In in vivo test using tumor model mice injected with B16BL6 cell line, mice treated with 10 and 100 μg/ml schizandrin showed a significant inhibition by 73.79 ± 6.43% and 90.46 ± 1.72%, respectively, compared with positive tumor controls. Schizandrin did not exert a significant toxicity for the normal cells (HUVECs) and tumor cell lines (A549, B16BL6, Du145, Huh7). Treatment with schizandrin at 10 and 100 μg/head significantly inhibited the tumor-induced angiogenesis by 68.04 ± 32.21% and 103.8 ± 34.99% compared with the positive control group, respectively. Using in vivo lung metastasis model, tumor metastasis assay revealed that 10 and 100 μg/head schizandrin significantly decreased the metastatic lung tumor by 37.51 ± 8.15% and 75.53 ± 4.38% compared with positive controls, respectively. On the other hand, schizandrin did not affect the adherence of B16BL6 cell line to extracellular matrix protein. These results demonstrate that schizandrin exerts inhibitory effect on tumor growth and metastasis by inhibiting angiogenesis. This study thus suggest that schizandrin may be a candidate molecule target for cancer drug development.

영어초록

Schizandra chinensis extract has been known to possess a variety of efficacy including antitumor. However, it remains unclear how schizandrin, which is a major biological active ingredient of Schizandra chinensis, exerts antitumor effect. This study was designed to investigate the mechanism by which schizandrin inhibits tumor growth and metastasis. In in vivo test using tumor model mice injected with B16BL6 cell line, mice treated with 10 and 100 μg/ml schizandrin showed a significant inhibition by 73.79 ± 6.43% and 90.46 ± 1.72%, respectively, compared with positive tumor controls. Schizandrin did not exert a significant toxicity for the normal cells (HUVECs) and tumor cell lines (A549, B16BL6, Du145, Huh7). Treatment with schizandrin at 10 and 100 μg/head significantly inhibited the tumor-induced angiogenesis by 68.04 ± 32.21% and 103.8 ± 34.99% compared with the positive control group, respectively. Using in vivo lung metastasis model, tumor metastasis assay revealed that 10 and 100 μg/head schizandrin significantly decreased the metastatic lung tumor by 37.51 ± 8.15% and 75.53 ± 4.38% compared with positive controls, respectively. On the other hand, schizandrin did not affect the adherence of B16BL6 cell line to extracellular matrix protein. These results demonstrate that schizandrin exerts inhibitory effect on tumor growth and metastasis by inhibiting angiogenesis. This study thus suggest that schizandrin may be a candidate molecule target for cancer drug development.

참고자료

· 없음